Letter to Editor Regarding “Nuclear Insulinoma-Associated Protein 1 Expression as a Marker of Neuroendocrine Differentiation in Neoplasms of the Breast” by Seijnhaeve et al
Restricted accessLetterFirst published online June, 2022
Letter to Editor Regarding “Nuclear Insulinoma-Associated Protein 1 Expression as a Marker of Neuroendocrine Differentiation in Neoplasms of the Breast” by Seijnhaeve et al
SeijnhaeveEGalantCVan BockstalMR. Nuclear insulinoma-associated protein 1 expression as a marker of neuroendocrine differentiation in neoplasms of the breast. Int J Surg Pathol. 2021;29:496–502.
2.
KawasakiTKairaK. Insulinoma-associated protein 1 (INSM1) expression in breast carcinomas with neuroendocrine morphologies: application and future prospective. Virchows Arch. 2021;479:191–194.
3.
RazviHTsangJYPoonIK, et al.INSM1 Is a novel prognostic neuroendocrine marker for luminal B breast cancer. Pathology. 2021;53:170–178.
4.
MetovicJCastellanoIMarinelliE, et al.INSM1 expression in breast neoplasms with neuroedocrine features. Endocr Pathol. 2021;32:452–460
5.
KawasakiTKairaKNakamuraY, et al. Re: INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer. Pathology. 2021;53:292–293.
6.
AllisonKHHammondMEHDowsettM, et al.Estrogen and progesterone receptor testing in breast cancer: American society of clinical oncology/college of American pathologists guideline update. Arch Pathol Lab Med. 2020;144:545–563.
